Latest 10-K annual reports

PreAxia Health Care Payment Systems Inc. filed an amended annual report, revealing a strategic pivot into AI-powered personal finance with its new Zane subsidiaries and significant capital requirements amidst ongoing losses.

The InterGroup Corporation reported a reduced net loss for fiscal year 2025, driven by improved hotel performance and a successful debt refinancing, while addressing Nasdaq compliance and internal control weaknesses.

Portsmouth Square, Inc. reports a reduced net loss for fiscal year 2025, driven by a successful debt refinancing and improved hotel operating metrics in San Francisco.

Dalrada Financial Corporation reports recurring losses and negative working capital, raising substantial doubt about its ability to continue as a going concern, despite some revenue growth in key segments.

Blackwell 3D Construction Corp. filed an amended annual report to remove shell company references, highlighting its ongoing development in 3D construction technology despite significant financial losses and a going concern warning.

Ready Capital Corporation filed an amendment to its 2024 Annual Report, primarily correcting certification errors, while detailing a strategic shift to LMM commercial real estate and small business lending, alongside significant financial performance changes including a net loss.

Damon Inc. reports significant losses and a going concern warning, with its shares delisted from Nasdaq and now trading on the OTCID Basic Market, as it continues electric motorcycle development.

AtlasClear Holdings, Inc. filed an amended annual report for fiscal year 2025, reporting a significant shift to net income despite ongoing liquidity concerns and internal control weaknesses.

The Glimpse Group, Inc. reported a significant reduction in net loss and increased revenue for fiscal year 2025, driven by a strategic shift to Spatial Computing and divestiture of non-core assets.

IDT Corporation's fiscal 2025 annual report highlights significant revenue and income growth across its fintech and communications segments, driven by strategic expansion and operational efficiencies.

Propanc Biopharma, a biopharmaceutical company, reported a significant increase in net loss to $58.9 million for fiscal year 2025, driven by substantial stock-based compensation, while advancing its lead cancer drug candidate, PRP, towards Phase Ib clinical trials.

Beneficient reported a significantly reduced net loss for fiscal year 2025, driven by legal settlements and lower operating expenses, though substantial doubt about its ability to continue as a going concern persists.

ReposiTrak, Inc. announced an 11% revenue increase and a 25% rise in net income for fiscal year 2025, alongside a 10% dividend increase and continued Preferred Stock redemptions.

Amesite Inc. shifts its core business to AI-powered healthcare solutions with NurseMagic, reporting reduced net losses but facing substantial doubt about its ability to continue as a going concern.

AtlasClear Holdings, Inc. reported a net income of $5.75 million for the fiscal year ended June 30, 2025, a significant improvement from the prior year's substantial loss, despite ongoing liquidity challenges and a 'going concern' warning.

MacKenzie Realty Capital, Inc. reported a significantly wider net loss for fiscal year 2025, driven by increased expenses and an impairment loss, leading to the suspension of common stock dividends.

VIP Play, Inc. reported a net loss of $18.9 million for fiscal year 2025, a significant improvement from the prior year, but faces substantial doubt about its ability to continue as a going concern without further financing.

Bion Environmental Technologies, Inc. reports significant financial challenges and leadership changes, pivoting its strategy towards bolt-on ammonia control solutions after writing down its Fair Oaks demonstration facility.

Neuphoria Therapeutics Inc. reports progress in its clinical pipeline for neuropsychiatric disorders, including BNC210 in Phase 3 for SAD and Phase 2b/3 for PTSD, alongside a $15 million milestone payment from Merck.

Okmin Resources, Inc. reported a net loss of $597,167 for fiscal year 2025, reduced its Blackrock JV interest, and increased its stake in the Pushmataha Gas Field, while facing significant going concern doubts and capital constraints.

NanoViricides, Inc. reports progress in broad-spectrum antiviral drug NV-387's clinical development, including Phase Ia/Ib completion, but faces significant financial constraints and a going concern doubt.

Lesaka Technologies reports significant net losses and internal control weaknesses for fiscal 2025, despite revenue growth driven by strategic acquisitions and expansion in Southern Africa's fintech market.

Anebulo Pharmaceuticals is prioritizing the development of an intravenous selonabant formulation for pediatric cannabis poisoning, while reporting continued operating losses and proposing a reverse stock split to go private.

Escalon Medical Corp. reported a slight increase in net revenue for fiscal year 2025, but auditors continue to express substantial doubt about the company's ability to continue as a going concern.

Precision Optics Corporation, Inc. reported a significant increase in net loss and a sharp decline in gross margin for the fiscal year ended June 30, 2025, despite flat revenues and successful capital raises.

NeoVolta, Inc. announced a significant increase in annual revenue for fiscal year 2025, driven by sales channel expansion, but reported a more than doubling of its net loss and increased cash burn.

Vail Resorts reports increased fiscal 2025 EBITDA and strategic capital investments, alongside a Whistler Blackcomb credit facility extension and reduction, while facing declining pass units and economic uncertainties.

5E Advanced Materials progresses its Fort Cady boron and lithium project with a $435 million Phase 1 capital estimate, targeting 2028 commercial production, despite ongoing significant losses and substantial doubt about its ability to continue as a going concern.

SR Bancorp, Inc. reported a significant increase in net income for the fiscal year ended June 30, 2025, driven by loan growth and strategic balance sheet restructuring, despite a material weakness in internal controls.

Lunai Bioworks Inc. reported a significant increase in net loss for fiscal year 2025, alongside a subsidiary's bankruptcy and ongoing legal challenges, raising substantial doubt about its ability to continue as a going concern.